Abstract
A delayed muscle relaxation after a voluntary contraction is the main clinical feature of myotonia congenita (MC). MC is a skeletal muscle channelopathy caused by loss-of-function mutations in the ClC-1 chloride channel, which impair channel function or plasma membrane expression. To date, no direct activator of ClC-1 channel is known. A potential strategy may be to restore surface expression of trafficking-defective ClC-1 mutants by using pharmacological chaperones. Thus, we tested the ability of niflumic acid (NFA), a reversible inhibitor of ClC-1, to restore membrane expression of MC ClC-1 mutants (A531V, V947E, G411C).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
